{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:55:58Z","timestamp":1791834958233,"version":"4.3.4"},"reference-count":41,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1210\/jc.2018-02202","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T09:08:52Z","timestamp":1552036132000},"page":"2527-2534","source":"Crossref","is-referenced-by-count":72,"title":["Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-6562","authenticated-orcid":false,"given":"Sema Ciftci","family":"Dogansen","sequence":"first","affiliation":[{"name":"Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul, Turkey"},{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Bak\u0131rkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-125X","authenticated-orcid":false,"given":"Ugur","family":"Cikrikcili","sequence":"additional","affiliation":[{"name":"Istanbul Faculty of Medicine, Department of Psychiatry, Istanbul University Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1998-4735","authenticated-orcid":false,"given":"Gonca","family":"Oruk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir Ataturk Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-988X","authenticated-orcid":false,"given":"Nilufer Ozdemir","family":"Kutbay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9220-6118","authenticated-orcid":false,"given":"Seher","family":"Tanrikulu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6003-0485","authenticated-orcid":false,"given":"Zeliha","family":"Hekimsoy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Celal Bayar University Medicine Faculty, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6197-5659","authenticated-orcid":false,"given":"Aysa","family":"Hadzalic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Erciyes University School of Medicine, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7646-7852","authenticated-orcid":false,"given":"Suheyla","family":"Gorar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Antalya Training and Research Hospital, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-9499","authenticated-orcid":false,"given":"Tulay","family":"Omma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Ankara Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-0915","authenticated-orcid":false,"given":"Meral","family":"Mert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Bak\u0131rkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5849-0071","authenticated-orcid":false,"given":"Gulhan","family":"Akbaba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Mugla S\u0131tk\u0131 Kocman University School of Medicine, Mugla, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9013-5237","authenticated-orcid":false,"given":"Gulsah Yenidunya","family":"Yalin","sequence":"additional","affiliation":[{"name":"Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9637-6744","authenticated-orcid":false,"given":"Fahri","family":"Bayram","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Erciyes University School of Medicine, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-9541","authenticated-orcid":false,"given":"Mine","family":"Ozkan","sequence":"additional","affiliation":[{"name":"Istanbul Faculty of Medicine, Department of Psychiatry, Istanbul University Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-9618","authenticated-orcid":false,"given":"Sema","family":"Yarman","sequence":"additional","affiliation":[{"name":"Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"issue":"1","key":"2019051808395661800_B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"issue":"2","key":"2019051808395661800_B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019051808395661800_B3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/13543784.11.6.787","article-title":"Dopamine receptor agonists for treating prolactinomas","volume":"11","author":"Colao","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"2019051808395661800_B4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"issue":"3","key":"2019051808395661800_B5","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Clinical review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2019051808395661800_B6","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders-Text Revision (DSM-IV TR)","author":"American Psychiatric Association","year":"2000"},{"key":"2019051808395661800_B7","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Health Disorders-V (DSM-V)","author":"American Psychiatric Association","year":"2013"},{"issue":"3","key":"2019051808395661800_B8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Prospective cohort study of impulse control disorders in Parkinson\u2019s disease","volume":"28","author":"Bastiaens","year":"2013","journal-title":"Mov Disord"},{"issue":"1","key":"2019051808395661800_B9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf"},{"key":"2019051808395661800_B10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fneur.2018.00330","article-title":"Impulse-control disorders in parkinson\u2019s disease: a meta-analysis and review of case-control studies","volume":"9","author":"Molde","year":"2018","journal-title":"Front Neurol"},{"issue":"2","key":"2019051808395661800_B11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"issue":"4","key":"2019051808395661800_B12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"2019051808395661800_B13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","article-title":"Pathological gambling and hypersexuality in cabergoline-treated prolactinoma","volume":"190","author":"Falhammar","year":"2009","journal-title":"Med J Aust"},{"key":"2019051808395661800_B14","author":"Gupta","year":"2011"},{"key":"2019051808395661800_B15","author":"Nannenga","year":"2011"},{"issue":"4","key":"2019051808395661800_B16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psym.2012.10.002","article-title":"Dopamine agonist-induced impulse control disorders in a patient with prolactinoma","volume":"54","author":"Almanzar","year":"2013","journal-title":"Psychosomatics"},{"issue":"5","key":"2019051808395661800_B17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","article-title":"Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma","volume":"36","author":"Thondam","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"2019051808395661800_B18","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"issue":"6","key":"2019051808395661800_B19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13339","article-title":"Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma","volume":"86","author":"Bulwer","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2019051808395661800_B20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0269881106073109","article-title":"New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson\u2019s disease: the role of dopamine agonist treatment and age at motor symptoms onset","volume":"21","author":"Giladi","year":"2007","journal-title":"J Psychopharmacol"},{"issue":"6","key":"2019051808395661800_B21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","article-title":"Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease","volume":"35","author":"Perez-Lloret","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"13","key":"2019051808395661800_B22","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.25557","article-title":"Impulse control disorders and related behaviors in Indian patients with Parkinson\u2019s disease","volume":"28","author":"Sarathchandran","year":"2013","journal-title":"Mov Disord"},{"issue":"8","key":"2019051808395661800_B23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.parkreldis.2014.05.014","article-title":"Impulse control and related disorders in Mexican Parkinson\u2019s disease patients","volume":"20","author":"Rodr\u00edguez-Violante","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"2019051808395661800_B24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"5","key":"2019051808395661800_B25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"2019051808395661800_B26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019051808395661800_B27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"issue":"3","key":"2019051808395661800_B28","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"issue":"10","key":"2019051808395661800_B29","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord"},{"issue":"6","key":"2019051808395661800_B30","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","article-title":"Factor structure of the Barratt impulsiveness scale","volume":"51","author":"Patton","year":"1995","journal-title":"J Clin Psychol"},{"issue":"4","key":"2019051808395661800_B31","first-page":"251","article-title":"Psychometric properties of the Turkish version of the Barratt impulsiveness scale-11","volume":"18","author":"Gulec","year":"2008","journal-title":"Klinik Psikofarmakol B\u00fclteni"},{"issue":"12","key":"2019051808395661800_B32","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"5","key":"2019051808395661800_B33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archneur.61.5.641","article-title":"The neurobiology of dopamine signaling","volume":"61","author":"Girault","year":"2004","journal-title":"Arch Neurol"},{"key":"2019051808395661800_B34","volume-title":"Rang&Dale\u2019s Pharmacology","author":"Rang","year":"2012","edition":"7th ed."},{"issue":"8","key":"2019051808395661800_B35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.parkreldis.2011.06.001","article-title":"Impulse control disorders in Chinese Parkinson\u2019s disease patients: the effect of ergot derived dopamine agonist","volume":"17","author":"Auyeung","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"2019051808395661800_B36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","article-title":"Impulse control disorders in Parkinson disease: a multicenter case-control study","volume":"69","author":"Voon","year":"2011","journal-title":"Ann Neurol"},{"issue":"3","key":"2019051808395661800_B37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.parkreldis.2009.12.002","article-title":"Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease","volume":"16","author":"Lee","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2019051808395661800_B38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019051808395661800_B39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1530\/EJE-12-0198","article-title":"Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas","volume":"167","author":"Athanasoulia","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2019051808395661800_B40","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1176\/appi.ajp.158.11.1783","article-title":"Psychiatric aspects of impulsivity","volume":"158","author":"Moeller","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2019051808395661800_B41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12020-017-1247-z","article-title":"Hypersexuality in men with prolactinomas treated with dopamine agonists","volume":"56","author":"Bancos","year":"2017","journal-title":"Endocrine"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/7\/2527\/28670945\/jc.2018-02202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T17:09:41Z","timestamp":1574269781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/7\/2527\/5371252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,3,8]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-02202","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,3,8]]}}}